New-onset atrial fibrillation in critically ill COVID-19 patients admitted to the ICU was associated with a significantly higher risk of ICU mortality (RR 1.39; 95% CI 1.07-1.80; P=0.01).
Meta-Analysis
Does new-onset atrial fibrillation increase the risk of complications and mortality in critically ill COVID-19 patients admitted to the ICU?
New-onset atrial fibrillation in critically ill COVID-19 patients in the ICU is associated with significantly higher risks of mortality, mechanical ventilation, acute myocardial infarction, and acute kidney injury.
Relative Risk: 1.39 (95% CI 1.07–1.8)
p-value: p=0.01
BACKGROUND: COVID-19 infections can result in severe acute respiratory distress syndrome (ARDS) requiring admission to the intensive care unit (ICU). Cardiovascular manifestation or exacerbation of cardiovascular diseases could be another complication. Cardiac arrhythmias including New-Onset Atrial Fibrillation (NOAF), have been observed in hospitalized patients with COVID-19 infections. In this analysis, we aimed to systematically compare the complications associated with NOAF in critically ill COVID-19 patients admitted to the ICU. METHODS: MEDLINE, EMBASE, Web of Science, the Cochrane database, http://www. CLINICALTRIALS: gov , Google Scholar and Mendeley were searched for relevant publications based on COVID-19 patients with NOAF admitted to the ICU. Complications including in-hospital mortality, ICU mortality, patients requiring mechanical ventilation, acute myocardial infarction, acute kidney injury, renal replacement therapy and pulmonary embolism were assessed. This is a meta-analysis and the analytical tool which was used was the RevMan software version 5.4. Risk ratios (RR) and 95% confidence intervals (CIs) were used to represent the data post analysis. RESULTS: In critically ill COVID-19 patients with NOAF admitted to the ICU, the risks of ICU mortality (RR: 1.39, 95% CI: 1.07 - 1.80; P = 0.01), in-hospital mortality (RR: 1.56, 95% CI: 1.20 - 2.04; P = 0.001), patients requiring mechanical ventilation (RR: 1.32, 95% CI: 1.04 - 1.66; P = 0.02) were significantly higher when compared to the control group without AF. Acute myocardial infarction (RR: 1.54, 95% CI: 1.31 - 1.81; P = 0.00001), the risk for acute kidney injury (RR: 1.31, 95% CI: 1.11 - 1.55; P = 0.002) and patients requiring renal replacement therapy (RR: 1.83, 95% CI: 1.60 - 2.09; P = 0.00001) were also significantly higher in patients with NOAF. CONCLUSIONS: Critically ill COVID-19 patients with NOAF admitted to the ICU were at significantly higher risks of developing complications and death compared to similar patients without AF.
Zhang et al. (2024) conducted a meta-analysis in COVID-19. New-Onset Atrial Fibrillation (NOAF) vs. Patients without atrial fibrillation was evaluated on ICU mortality (RR 1.39, 95% CI 1.07 - 1.80, p=0.01). New-onset atrial fibrillation in critically ill COVID-19 patients admitted to the ICU was associated with a significantly higher risk of ICU mortality (RR 1.39; 95% CI 1.07-1.80; P=0.01).